Ricerca avanzata

Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 2001 Marzo;45(1) > The Quarterly Journal of Nuclear Medicine 2001 Marzo;45(1):47-52

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Periodicità: Trimestrale

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine 2001 Marzo;45(1):47-52

NUCLEAR MEDICINE APPLICATIONS FOR BONE METASTASES 

Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography

Cook G. J. R., Fogelman I. *

From the Department of Nuclear Medicine Royal Marsden Hospital, Sutton, Surrey, UK
*Department of Nuclear Medicine Guys Hospital, London, UK

The use of posi­tron emis­sion tomog­ra­phy (PET) in clin­i­cal oncol­o­gy con­tin­ues to ­increase and ­although ­there is now a ­large lit­er­a­ture on the use of PET ­with var­i­ous trac­ers in a ­wide varie­ty of can­cers, ­there has pre­vi­ous­ly ­been rel­a­tive­ly lit­tle use spe­cif­i­cal­ly in the eval­u­a­tion of skel­e­tal metas­ta­ses. However, a num­ber of ­reports on PET in ­this ­area of oncol­o­gy are now becom­ing avail­able. The poten­tial advan­tag­es of PET ­over con­ven­tion­al nucle­ar med­i­cine tech­niques, includ­ing ­improved spa­tial res­o­lu­tion, abso­lute quan­ti­ta­tion and the acqui­si­tion of tom­o­graph­ic stud­ies as a rou­tine, are ­also of poten­tial ben­e­fit in ­this ­area. The ­bone ­agent, 18F-flu­o­ride and the ­tumour ­agent 18F-flu­o­rod­e­ox­y­glu­cose, ­have ­been ­used to eval­u­ate ­both ­benign and malig­nant skel­e­tal dis­or­ders qual­ita­tive­ly and quan­ti­ta­tive­ly and the cur­rent knowl­edge ­with ­respect to the skele­ton in can­cer ­patients is sum­mar­ised in ­this arti­cle.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina